triple-negative breast cancer
Generated by DeepSeek V3.2Expansion Funnel Raw 66 → Dedup 39 → NER 10 → Enqueued 9
| triple-negative breast cancer | |
|---|---|
| Name | Triple-negative breast cancer |
| Synonyms | TNBC |
| Field | Oncology |
| Risks | BRCA1, BRCA2 |
| Diagnosis | Immunohistochemistry, Fluorescence in situ hybridization |
| Treatment | Chemotherapy, Immunotherapy, PARP inhibitor |
| Frequency | 10-20% of Breast cancer |
triple-negative breast cancer is a subtype of Breast cancer characterized by the absence of three specific Receptor (biochemistry)s: the Estrogen receptor, the Progesterone receptor, and the HER2 protein. This molecular profile makes it unresponsive to common Hormonal therapy and Trastuzumab, which target these receptors, necessitating different therapeutic strategies. It is often more aggressive and has a higher likelihood of recurrence than other breast cancer subtypes, presenting significant clinical challenges.
Overview
Triple-negative breast cancer is defined by its lack of expression of Estrogen receptor, Progesterone receptor, and HER2 upon Pathology testing. This classification places it within the broader category of Basal-like breast cancers, although the terms are not entirely synonymous. The disease is associated with distinct Gene expression patterns and often harbors mutations in genes like BRCA1. Its aggressive nature is reflected in its higher Histological grade and frequent presentation as an Interval cancer between screening mammograms. Research into its biology is a major focus at institutions like the National Cancer Institute and the European Society for Medical Oncology.
Diagnosis
Diagnosis is confirmed through pathological assessment of a Biopsy specimen using techniques such as Immunohistochemistry and Fluorescence in situ hybridization to evaluate receptor status. Imaging studies, including Mammography and Magnetic resonance imaging, are critical for staging and often reveal features like a Mass (medicine) with irregular margins. The American Joint Committee on Cancer TNM staging system is used to determine the extent of disease. Differential diagnosis from other aggressive subtypes, such as Inflammatory breast cancer, is essential. Guidelines from the American Society of Clinical Oncology and the College of American Pathologists standardize the diagnostic criteria.
Treatment
Standard treatment typically involves Neoadjuvant chemotherapy with regimens containing Anthracyclines and Taxanes, aiming for a Pathological complete response. For patients with BRCA1 or BRCA2 mutations, PARP inhibitors like Olaparib are approved options. The advent of Immunotherapy, particularly Atezolizumab and Pembrolizumab in combination with chemotherapy, has shown efficacy in PD-L1-positive metastatic disease. Radiation therapy and Mastectomy or Lumpectomy are standard local therapies. Clinical trials through cooperative groups like the Eastern Cooperative Oncology Group are vital for advancing care.
Prognosis
Prognosis is generally poorer compared to Hormone receptor positive breast cancers, with a higher risk of Distant metastasis to sites like the Brain and Lungs, and earlier recurrence, often within the first five years. Achieving a Pathological complete response after neoadjuvant chemotherapy is a strong positive prognostic factor. Survival rates are tracked by databases such as the Surveillance, Epidemiology, and End Results program. Research into Biomarker (medicine)s, including Tumor-infiltrating lymphocytes and Ki-67, aims to better predict outcomes.
Epidemiology
This subtype accounts for approximately 10-20% of all Breast cancer diagnoses. It is disproportionately more common in younger women, particularly those of African American and Hispanic descent, and in individuals with BRCA1 mutations. Geographic variation in incidence is studied by organizations like the World Health Organization. Risk factors also include lower Socioeconomic status and certain Reproductive history patterns. The International Agency for Research on Cancer monitors its global burden.
Research
Ongoing research is highly active, focusing on understanding its heterogeneous biology through platforms like The Cancer Genome Atlas. Key areas include developing novel Chemotherapy agents, Antibody-drug conjugates such as Sacituzumab govitecan, and targeting pathways like the PI3K/AKT/mTOR pathway and Androgen receptor. Major trials are conducted by the National Surgical Adjuvant Breast and Bowel Project and presented at forums like the San Antonio Breast Cancer Symposium. Investigations into the Tumor microenvironment and Cancer stem cells are also promising frontiers.